Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Narrative)

v3.23.1
Commitments and Contingencies (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Apr. 30, 2020
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Product Liability Contingency [Line Items]          
Research and Development Expense   $ 3,567,759 $ 1,888,803    
Repayments of Related Party Debt       $ 800,000  
Development fees $ 1,000,000.0        
Payment for fees $ 775,000        
Houston Pharmaceuticals [Member]          
Product Liability Contingency [Line Items]          
Cost of Goods and Services Sold   0 41,075    
Officers [Member]          
Product Liability Contingency [Line Items]          
Cash bonuses approved   550,750      
Scientific Advisory Board [Member]          
Product Liability Contingency [Line Items]          
Labor and Related Expense   0 48,684    
Mr Hsu Scientific Advisory Board [Member]          
Product Liability Contingency [Line Items]          
Deferred Compensation Liability, Current   117,284      
Houston Pharm [Member] | Technology Rights Agreement [Member]          
Product Liability Contingency [Line Items]          
Royalty Income, Nonoperating   12,500 87,500    
UTMDACC [Member] | Patent And Technology License Agr [Member]          
Product Liability Contingency [Line Items]          
License fee   11,744 $ 44,424    
UTMDACC [Member] | Sponsored Research Agreement [Member]          
Product Liability Contingency [Line Items]          
License fee         $ 334,000
Research and Development Expense         $ 400,000
WPD [Member] | Development Agreement [Member]          
Product Liability Contingency [Line Items]          
Development fees   $ 225,000